Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00664
|
|||||
| Drug Name |
Trifluoperazine
|
|||||
| Synonyms |
10-(3-(4-Methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)phenothiazine; 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-10H-phenothiazine; 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-phenothiazine; 10-(gamma-(N'-Methylpiperazino)propyl)-2-trifluoromethylphenothiazine; 10-[3-(4-METHYL-PIPERAZIN-1-YL)-PROPYL]-2-TRIFLUOROMETHYL-10H-PHENOTHIAZINE; 10-[3-(4-Methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-10H-phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)-10H-phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine dihydrochloride; 2-Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine; Apo-Trifluoperazine; Apo-trifluoperazine (TN); Calmazine; Eskazine; Eskazine (TN); Eskazinyl (TN); Fluoperazine; Flurazine; Jatroneural (TN); Modalina; Modalina (TN); NCI17474; Novo-Trifluzine; PMS Trifluoperazine; RP 7623; SKF 5019; Stelazine; Stelazine (*Dihydrochloride*); Stelazine (TN); Stelazine Concentrate; Stellazine; TFP; Terfluzine (TN); Trifluoperaz (TN); Trifluoperazin; Trifluoperazina; Trifluoperazina [INN-Spanish]; Trifluoperazina [Italian]; Trifluoperazine (INN); Trifluoperazine HCl; Trifluoperazine [INN:BAN]; Trifluoperazine dihydrochloride; Trifluoperazinum; Trifluoperazinum [INN-Latin]; Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine; Trifluoromethylperazine; Trifluoroperazine; Trifluoroperazine dihydrochloride; Trifluperazine; Triflurin; Trifluroperizine; Triftazin; Triftazine; Triperazine; Tripfluoperazine Hydrochloride; Triphtazin; Triphtazine; Triphthasine
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Schizophrenia [ICD11:6A20] | Approved | [1] | |||
| Generalized non-psychotic anxiety [ICD11:6B00] | Approved | [1] | ||||
| Therapeutic Class |
Antipsychotic Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C21H24F3N3S
|
|||||
| Canonical SMILES |
CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F
|
|||||
| InChI |
InChI=1S/C21H24F3N3S/c1-25-11-13-26(14-12-25)9-4-10-27-17-5-2-3-6-19(17)28-20-8-7-16(15-18(20)27)21(22,23)24/h2-3,5-8,15H,4,9-14H2,1H3
|
|||||
| InChIKey |
ZEWQUBUPAILYHI-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 117-89-5
|
|||||
| Pharmaceutical Properties | Molecular Weight | 407.5 | Topological Polar Surface Area | 35 | ||
| Heavy Atom Count | 28 | Rotatable Bond Count | 4 | |||
| Hydrogen Bond Donor Count | 0 | Hydrogen Bond Acceptor Count | 7 | |||
| XLogP |
5
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10319712
,10505141
,11110644
,11110645
,11120338
,11120826
,11121314
,11121780
,11122260
,11336018
,11361257
,11362944
,11363562
,11364843
,11365506
,11366124
,11367405
,11368068
,11368686
,11369967
,11371059
,11371060
,11372247
,11373007
,11373669
,11373974
,11375567
,11376230
,11376848
,11378135
,11405822
,11408478
,11458546
,11460495
,11462229
,11466341
,11467461
,11484491
,11486261
,11488644
,11491189
,11492183
,11494482
,4252673
,5664287
,602753
,7890752
,7980830
,841996
,9377
|
|||||
| ChEBI ID |
ChEBI:45951
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Trifluoperazine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.